Sustained IL-2R signaling of limited duration by high-dose mIL-2/mCD25 fusion protein amplifies tumor-reactive CD8+ T cells to enhance antitumor immunity
Authors:
- 10 October 2020
- journal article
- research article
- Published by Springer Nature in Cancer Immunology, Immunotherapy
- Vol. 70 (4) , 909-921
Abstract
High-dose IL-2 induces cancer regression but its therapeutic use is limited due to high toxicities resulting from its broad cell targeting. In one strategy to overcome this limitation, IL-2 has been modified to selectively target the intermediate affinity IL-2R that broadly activates memory-phenotypic CD8+ T and NK cells, while minimizing Treg-associated tolerance. In this study, we modeled an alternative strategy to amplify tumor antigen-specific TCR transgenic CD8+ T cells through limited application of a long-acting IL-2 fusion protein, mIL-2/mCD25, which selectively targets the high-affinity IL-2R. Here, mice were vaccinated with a tumor antigen and high-dose mIL-2/mCD25 was applied to coincide with the induction of the high affinity IL-2R on tumor-specific T cells. A single high dose of mIL-2/mCD25, but not an equivalent amount of IL-2, amplified the frequency and function of tumor-reactive CD8+ T effector (Teff) and memory cells. These mIL-2/mCD25-dependent effects relied on distinctive requirements for TLR signals during priming of CD8+ tumor-specific T cells. The mIL-2/mCD25-amplified tumor-reactive effector and memory T cells supported long-lasting antitumor responses to B16-F10 melanoma. This regimen only transiently increased Tregs, yielding a favorable Teff–Treg ratio within the tumor microenvironment. Notably, mIL-2/mCD25 did not increase non-tumor-specific Teff or NK cells within tumors, further substantiating the specificity of mIL-2/mCD25 for tumor antigen-activated T cells. Thus, the selectivity and persistence of mIL-2/mCD25 in conjunction with a tumor vaccine supports antitumor immunity through a mechanism that is distinct from recombinant IL-2 or IL-2-based biologics that target the intermediate affinity IL-2R.Keywords
Funding Information
- National Institutes of Health (R21CA195334)
- Sylvester Comprehensive Cancer Center
This publication has 33 references indexed in Scilit:
- Human IL-2 Mutein with Higher Antitumor Efficacy Than Wild Type IL-2The Journal of Immunology, 2013
- Interleukin-2 Receptor Signaling: At the Interface between Tolerance and ImmunityImmunity, 2010
- The repeat domain of the melanosome fibril protein Pmel17 forms the amyloid core promoting melanin synthesisProceedings of the National Academy of Sciences, 2009
- Tumor Regression following DNA Vaccination and Regulatory T Cell Depletion in neu Transgenic Mice Leads to an Increased Risk for AutoimmunityThe Journal of Immunology, 2009
- Blimp-1 directly represses Il2 and the Il2 activator Fos, attenuating T cell proliferation and survivalJournal of Experimental Medicine, 2008
- Selective Stimulation of T Cell Subsets with Antibody-Cytokine Immune ComplexesScience, 2006
- IL-2 production in developing Th1 cells is regulated by heterodimerization of RelA and T-bet and requires T-bet serine residue 508Journal of Experimental Medicine, 2005
- Defining the Antigen-Specific T-Cell Response to Vaccination and Poly(I:C)/TLR3 SignalingJournal of Immunotherapy, 2005
- Tumor Regression and Autoimmunity after Reversal of a Functionally Tolerant State of Self-reactive CD8+ T CellsJournal of Experimental Medicine, 2003
- T cell receptor antagonist peptides induce positive selectionCell, 1994